Alessandro Leonetti

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Giulia Mazzaschi, Roberta Minari, Alessandra Zecca et al. · Lung Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 84 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Alessandro Leonetti, Roberta Minari, Luca Boni et al. · Clinical Lung Cancer · 2021 · 63 citations

Medicine, Oncology, Surgery +17

Smoking status during first‐line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A case–control matched analysis from a large multicenter study

Alessio Cortellini, Andrea De Giglio, Katia Cannita et al. · Thoracic Cancer · 2021 · 47 citations · Full text

Medicine, Immunology, Oncology +13